Evidence map›Paper›PMID 29888640›Full record

ArticleCell cycle (Georgetown, Tex.)2018

MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.

Tiechao Jiang, Dongming Sui, Dong You, Songmei Yao, Lirong Zhang, Yingjian Wang, Jixue Zhao, Yaozhong Zhang

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Non-Coding RNAs as Prognostic Markers for Endometrial Cancer.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tiechao Jianga Department of Cardiology , China-Japan Union Hospital of Jilin University , Jilin , China.
Dongming Suic Department of Asset Management , The First Hospital of Jilin University , Jilin , China.
Dong Youd Department of Thoracic Surgery , The First Hospital of Jilin University , Jilin , China.
Songmei Yaoe Department of Traditional Chinese Medicine , China-Japan Union Hospital of Jilin University , Jilin , China.
Lirong Zhangf Department of Pathology , China-Japan Union Hospital of Jilin University , Jilin , China.
Yingjian Wangg Department of Gynaecology and Obstetrics , China-Japan Union Hospital of Jilin University , Jilin , China.
Jixue Zhaoh Department of Pediatric Surgery , The First Hospital of Jilin University , Jilin , China.
Yaozhong Zhangi Department of Anesthesiology , China-Japan Union Hospital of Jilin University , Jilin , China.
Jilin University · CNFirst Hospital of Jilin University · CNHealth Commission of Jilin Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was aimed to explore the effects of miR-29a-5p expression and its target gene TPX2 (target protein for Xenopus kinesin-like protein 2) on endometrial cancer (EC) devel on EC development and to assess the prognostic impacts of TPX2. Microarray-based GEO and TCGA (the Cancer Genome Atlas) EC expression data were used to identify differentially expressed miRNAs and mRNAs. The observed potential target relationship between miR-29a-5p and TPX2 was verified using TargetScan and luciferase reporter assays. The mRNA and protein expression levels of miR-29a-5p and TPX2 were confirmed by qRT-PCR and western blot, respectively. Associations between TPX2 expression and patient prognosis were assessed using Kaplan-Meier and log-rank assays. Changes in EC-derived cell proliferation, invasion and apoptosis after exogenous miR-29a-5p and TPX2 over-expression and/or silencing were assessed using CCK-8 (cell counting kit-8), colony formation, Transwell and flow cytometry assays, respectively. We found that in primary EC tissues the expression of miR-29a-5p was down-regulated and the expression of TPX2 was up-regulated. We also found that low expression of TPX2 were associated with a better prognosis, and vice versa. Subsequent exogenous miR-29a-5p over-expression and TPX2 silencing could inhibit EC-derived cell proliferation and invasion, and to induce apoptosis. We also found that miR-29a-5p might target and repress TPX2, thereby inhibiting EC-derived cell proliferation and invasion and enhancing apoptosis. We conclude that miR-29a-5p could inhibit the proliferation and invasion of EC-derived cells and enhance the apoptosis of EC-derived cells via TPX2 down-regulation. A high TPX2 expression in primary EC tissues was found to be associated with a poor prognosis. As such, these biomarkers may serve as promising prognostic indicators. ABBREVIATIONS: EC: Endometrial cancer; 3'-UTR: 3'-untranslated regions; TPX2: target protein for Xenopus kinesin-like protein 2; TCGA: the Cancer Genome Atlas; UCEC: uterine corpus endometrial carcinoma; CCK-8: cell counting kit-8; OD: optical density; FCM: flow cytometry; EMT: epithelial-mesenchymal transition.

Indexed as

AnimalsApoptosisBase SequenceCell Cycle ProteinsCell Line, TumorCell ProliferationDown-RegulationEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMice, Inbred BALB CMice, NudeMicroRNAsMicrotubule-Associated ProteinsMiddle AgedCell Cycle ProteinsMicroRNAsMicrotubule-Associated ProteinsMIRN29a microRNA, humanNuclear ProteinsTPX2 protein, humanEndometrial carcinomaMiR-29a-5pTPX2

Identifiers

PMID29888640
PMCPMC6110586
OpenAlexW2806297520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.